FDA AND POST-MARKET SURVEILLANCE

Post-Marketing Activities
Elliot P. Cowan, PhD
Partners in Diagnostics, LLC
Purpose of this Talk

• To show what FDA expects for post-market surveillance activities
• To discuss actions FDA takes to respond to post-market issues
• To understand the implications of changes to an approved product
Overview

From: Strengthening Our National System for Medical Device Postmarket Surveillance: Update and Next Steps
Center For Devices And Radiological Health U.S. Food And Drug Administration. April 2013
Manufacturer’s Responsibilities (1)

• As part of compliance with the QSRs, manufacturers must have:
  – Adequate complaint handling system
  – Adequate corrective and preventive action procedures to determine the root cause of problems and implement changes to prevent them from happening in the future
Manufacturer’s Responsibilities (2)

• Regulatory requirement for mandatory reporting to FDA of certain device-related adverse events and product problems (Medical Device Reporting)
  – Required of manufacturers, importers, and users
  – When device may have caused or contributed to a death or serious injury
  – When device malfunctions and would likely contribute to a death or serious injury if that malfunction were to recur

• Voluntary reporting
The Public’s Responsibilities

• Register complaints to manufacturer and to FDA
  – Test performance not consistent with claims in package insert/instructions for use
  – Quality issues

• MedWatch reporting
Triggers for Reporting: Test Performance

• False positive results
  – Reactive rapid HIV test result must be confirmed
  – Higher than expected rate of results that do not confirm positive

• False negative results
  – Typically identified through research studies
Examples

- Reports of sporadic, localized increased rate of false positive results


- Reports of false negative results
  - Window period testing
  - Documented false negatives with oral fluid specimens from individuals on anti-retroviral therapy
FDA Responsibilities

• Routine inspections for Class III IVDs (at least every 2 years) to monitor for continued QSR compliance

• Follow up with manufacturer on issues reported to FDA
  – Contact manufacturer
  – Ensure investigation conducted, root cause identified, and corrective action taken
  – For-cause inspection, if necessary

• Compliance actions, if necessary
FDA Enforcement Tools (1)

- Approved/cleared tests
  - Letters to manufacturers
  - Recalls
    - Voluntary action to carry out manufacturer’s responsibility to protect the public health with respect to its products
  - Injunction and seizure (judicial actions for US manufacturers)
  - Application integrity policy (action taken in the event of fraud and misrepresentation)
FDA Enforcement Tools (2)

• Unapproved/uncleared tests (e.g., marketed through the Internet)
  – Letters (made public)
  – Import alert (for non-US manufacturers)
  – Court action to prevent sale (for US manufacturers, after gathering evidence)
Changes to an Approved Product

- Manufacturers make changes to their products to
  - Improve efficiency of the manufacturing process
  - Change suppliers of materials/components
  - Correct errors
  - Address problems
  - Other reasons
Changes to the IVD

Guidance for Industry and FDA Staff

Modifications to Devices Subject to Premarket Approval (PMA) - The PMA Supplement Decision-Making Process

Document Issued on: December 11, 2008

This document supersedes “Modifications to Devices Subject to Premarket Approval (PMA) - The PMA Supplement Decision-Making Process” dated March 9, 2007.

http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm089274.htm
Assessing Changes

What is the potential for the change to affect the safety and effectiveness of the product?
Thank You